OMER
Price
$4.18
Change
-$0.11 (-2.56%)
Updated
Sep 3 closing price
Capitalization
284.47M
62 days until earnings call
SAVA
Price
$2.21
Change
-$0.06 (-2.64%)
Updated
Sep 3 closing price
Capitalization
107M
62 days until earnings call
Interact to see
Advertisement

OMER vs SAVA

Header iconOMER vs SAVA Comparison
Open Charts OMER vs SAVABanner chart's image
Omeros
Price$4.18
Change-$0.11 (-2.56%)
Volume$767.81K
Capitalization284.47M
Cassava Sciences
Price$2.21
Change-$0.06 (-2.64%)
Volume$479.94K
Capitalization107M
OMER vs SAVA Comparison Chart in %
Loading...
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OMER vs. SAVA commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OMER is a Hold and SAVA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (OMER: $4.29 vs. SAVA: $2.27)
Brand notoriety: OMER and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OMER: 63% vs. SAVA: 74%
Market capitalization -- OMER: $284.47M vs. SAVA: $107M
OMER [@Biotechnology] is valued at $284.47M. SAVA’s [@Biotechnology] market capitalization is $107M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OMER’s FA Score shows that 1 FA rating(s) are green whileSAVA’s FA Score has 1 green FA rating(s).

  • OMER’s FA Score: 1 green, 4 red.
  • SAVA’s FA Score: 1 green, 4 red.
According to our system of comparison, OMER is a better buy in the long-term than SAVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OMER’s TA Score shows that 3 TA indicator(s) are bullish while SAVA’s TA Score has 5 bullish TA indicator(s).

  • OMER’s TA Score: 3 bullish, 3 bearish.
  • SAVA’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than OMER.

Price Growth

OMER (@Biotechnology) experienced а -2.05% price change this week, while SAVA (@Biotechnology) price change was +0.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

OMER is expected to report earnings on Nov 05, 2025.

SAVA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OMER($284M) has a higher market cap than SAVA($107M). SAVA YTD gains are higher at: -3.814 vs. OMER (-56.579). OMER (-125.18M) and SAVA (-129.96M) have comparable annual earnings (EBITDA) . SAVA has more cash in the bank: 112M vs. OMER (28.7M). SAVA has less debt than OMER: SAVA (0) vs OMER (184M). OMER (0) and SAVA (0) have equivalent revenues.
OMERSAVAOMER / SAVA
Capitalization284M107M265%
EBITDA-125.18M-129.96M96%
Gain YTD-56.579-3.8141,484%
P/E RatioN/AN/A-
Revenue00-
Total Cash28.7M112M26%
Total Debt184M0-
FUNDAMENTALS RATINGS
OMER vs SAVA: Fundamental Ratings
OMER
SAVA
OUTLOOK RATING
1..100
7982
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
22
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1199
PRICE GROWTH RATING
1..100
5463
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (22) in the Pharmaceuticals Other industry is in the same range as OMER (38) in the Biotechnology industry. This means that SAVA’s stock grew similarly to OMER’s over the last 12 months.

SAVA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as OMER (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to OMER’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for SAVA (99) in the Pharmaceuticals Other industry. This means that OMER’s stock grew significantly faster than SAVA’s over the last 12 months.

OMER's Price Growth Rating (54) in the Biotechnology industry is in the same range as SAVA (63) in the Pharmaceuticals Other industry. This means that OMER’s stock grew similarly to SAVA’s over the last 12 months.

OMER's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SAVA (100) in the Pharmaceuticals Other industry. This means that OMER’s stock grew similarly to SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OMERSAVA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 22 days ago
83%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNGNF3.42N/A
N/A
Singapore Telecommunications Ltd.
GBMCF0.12N/A
N/A
Green Bridge Metals Corporation
CDNTF193.33N/A
N/A
Canadian Tire Corp. Ltd.
CMRB4.80-0.10
-2.04%
First Commerce Bancorp Inc.
FKRAF16.52-0.64
-3.74%
Fiskars OY AKT

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with INM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then INM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
+3.13%
INM - OMER
46%
Loosely correlated
-2.70%
ACIU - OMER
33%
Loosely correlated
+8.33%
TGTX - OMER
32%
Poorly correlated
+1.36%
MDXG - OMER
32%
Poorly correlated
+1.27%
FULC - OMER
32%
Poorly correlated
-1.08%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with PRRUF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then PRRUF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
-0.44%
PRRUF - SAVA
33%
Loosely correlated
N/A
OMER - SAVA
25%
Poorly correlated
+3.13%
CMPX - SAVA
23%
Poorly correlated
-1.72%
APLM - SAVA
22%
Poorly correlated
+7.08%
MREO - SAVA
22%
Poorly correlated
+3.51%
More